Pharmaceutical group · United States
Salix
A group of 3 companies with 21 medicines in 2 countries.
Group structure
3 companies in 2 countries
United States2
Canada1
Groups are put together by Prognia from the names regulators publish and from company links; they are not an official corporate structure.
Medicines
Every medicine of every company in the group, current ones first.
21 medicines
| Medicine | Substance | Country | Status | Authorised |
|---|---|---|---|---|
| ANUSOL HC2.5% · Cream | Hydrocortisone | United States | Marketed | 1984 |
| APRISO375mg · Capsule, extended release | Mesalazine | United States | Marketed | 2008 |
| DIURIL250mg/5ml · Suspension | Chlorothiazide | United States | Not marketed | 1961 |
| FENOGLIDE120MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | 40MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** · Tablet | Fenofibrate | United States | Not marketed | 2007 |
| METOZOLV ODT10MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | 5MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** · Tablet, orally disintegrating | Metoclopramide | United States | Not marketed | 2009 |
| MOVIPREP4.7gm; 3350 100gm; 1.015gm; 5.9gm; 2.691gm; 7.5gm · For solution | Ascorbic acid, Macrogol, Potassium chloride, Sodium chloride, Sodium sulfate | United States | Marketed | 2006 |
| OSMOPREP0.398GM; 1.102GM **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** · Tablet | Sodium phosphate, Dibasic, Anhydrous, Monobasic, Monohydrate | United States | Not marketed | 2006 |
| PEPCID40MG/5ML **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** · For suspension | Famotidine | United States | Not marketed | 1987 |
| PLENVU7.54gm; 3350 140gm; 2.2gm; 48.11gm; 5.2gm; 9gm · For solution | Ascorbic acid, Macrogol, Potassium chloride, Sodium chloride, Sodium sulfate | United States | Marketed | 2018 |
| RELISTOR150mg · Tablet | Methylnaltrexone bromide | United States | Marketed | 2016 |
| RELISTOR20 mg / ml · Solution | Methylnaltrexone bromide | Canada | Marketed | 2008 |
| RELISTOR12mg/0.6ml (12mg/0.6ml) | 8mg/0.4ml (8mg/0.4ml) · Solution | Methylnaltrexone bromide | United States | Marketed | 2008 |
| RELISTOR20 mg / ml · Solution | Methylnaltrexone bromide | Canada | Authorised | |
| RELISTOR20 mg / ml · Solution | Methylnaltrexone bromide | Canada | Authorised | |
| TRULANCE3MG · Tablet | Plecanatide | United States | Marketed | 2017 |
| UCERIS2mg/actuation · Aerosol, foam | Budesonide | United States | Marketed | 2014 |
| UCERIS9MG · Tablet, extended release | Budesonide | United States | Marketed | 2013 |
| VISICOL0.398gm; 1.102gm · Tablet | Sodium phosphate, Dibasic, Anhydrous, Monobasic, Monohydrate | United States | Not marketed | 2000 |
| XIFAXAN200mg | 550mg · Tablet | Rifaximin | United States | Marketed | 2004 |
| ZAXINE550 mg · Tablet | Rifaximin | Canada | Marketed | 2013 |
| ZEGERID20MG; 1.1GM **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | 40MG; 1.1GM **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** · Capsule | Omeprazole, Bicarbonate | United States | Not marketed | 2006 |